HEALTHCARE company Haleon yesterday reported a double-digit hike in revenue and profits in the group's first set of company results since it spun off from pharma giant Glaxosmithkline.

The company, which owns popular health products Sensodyne and Panadol, posted a 13.4 per cent rise in its revenue to £5.2bn in the first half of the year.

The firm's revenues were boosted by particularly strong sales across respiratory health products during the cold and flu season, the group reported.

Operating profits also grew by more than 22 per cent year-on-year, totalling £900m in the six months to 30 June.

Haleon said that it was well positioned to navigate the current macroeconomic challenges through the second half of the year, including rising inflation and the potential impact of higher prices on consumer buying behaviour.

However, the healthcare group said positive momentum continued at a slower rate into the third quarter, as expected.

Haleon, which employs around 22,000 staff around the world, split from Glaxosmithkline in July and floated on the London Stock Exchange in Europe's biggest listing for more than a decade.

PA

(c) 2022 City A.M., source Newspaper